Conference Vision

The world has witnessed the booming of gene and cell therapy (GCT) in these years. CGT is dubbed as the future industry that is expected to bring hope to cancer patients and is deemed as the next growth driver of biopharmaceutics industry.

In recent years, China’s cell and gene therapy (CGT) industry has developed substantially, contributing to around half of the registered CGT trials worldwide with some world-class breakthroughs. China ranked second only after the USA in cancer cell therapies pipeline numbers. According to the publisher, China cell and gene therapy market size is expected to record a CAGR of 20.2% during 2023-2027 to reach US$2.644 billion by 2027, increasing from US$1.053 billion in 2023. Over the last five years, the sector has recorded a CAGR of 25.7% to reach US$0.837 billion in 2022.

Although CGT market in China is flourishing, challenges related to clinical application, product specifications, CMC, quality control, comparability study, potent assay still exist and need to be addressed.

As part of Biologics Innovation and Frontier Technology (BIFT) summit series, GEC events is rolling out Cell & Gene Therapy Development and Innovation Shanghai Summit (CGDI Shanghai 2024), which will take place on September 2024 in Shanghai China. The event will review major issues affecting the industry and provide strategies for CGT companies to be successful in China and global markets. In order to better identify current opportunities and address future challenges of CGT industry in China, we are inviting gene and cell therapy thought leaders from the research, industry, and capital communities as well as representatives from regulatory bodies to focus on recent developments in CGT Commercialization, Manufacturing, Innovative Cell Therapy (CAR-NK, TIL, TCR-T and etc), CMC, Oncolytic Virus, mRNA Vaccine, Oligonucleotides, among many others.